The PE Ratio as of July 2024 (TTM) for NGM Biopharmaceuticals, Inc. (NGM) is -0.89

According to NGM Biopharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.89. This represents a change of -23.61% compared to the average of -1.17 of the last 4 quarters.

NGM Biopharmaceuticals, Inc. (NGM) Historical PE Ratio (quarterly & annually)

How has NGM PE Ratio performed in the past?

The mean historical PE Ratio of NGM Biopharmaceuticals, Inc. over the last ten years is -272.16. The current -0.89 PE Ratio has changed -67.29% with respect to the historical average. Over the past ten years (40 quarters), NGM's PE Ratio was at its highest in in the December 2018 quarter at 13.92. The PE Ratio was at its lowest in in the June 2018 quarter at -61.62.

NGM Biopharmaceuticals, Inc. (NGM) PE Ratio by Quarter and Year

Discovering the peaks and valleys of NGM Biopharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

NGM Biopharmaceuticals, Inc. (NGM) Average PE Ratio

How has NGM PE Ratio performed in the past?

The current PE Ratio of NGM Biopharmaceuticals, Inc. (NGM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

NGM Biopharmaceuticals, Inc. (NGM) PE Ratio vs. Peers

How is NGM’s PE Ratio compared to its peers?

NGM Biopharmaceuticals, Inc.’s PE Ratio is greater than Neoleukin Therapeutics, Inc. (-0.98), less than Instil Bio, Inc. (-0.66), less than Achilles Therapeutics plc (-0.52), less than NextCure, Inc. (-0.72), greater than Assembly Biosciences, Inc. (-1.60), greater than Erasca, Inc. (-3.91), greater than Century Therapeutics, Inc. (-1.17), greater than Keros Therapeutics, Inc. (-9.61), greater than Monte Rosa Therapeutics, Inc. (-2.08), greater than Nkarta, Inc. (-3.07), greater than Lyell Immunopharma, Inc. (-1.83), greater than Generation Bio Co. (-1.38), greater than Sana Biotechnology, Inc. (-4.51), less than Kezar Life Sciences, Inc. (-0.48), greater than Mineralys Therapeutics, Inc. (-6.65), greater than Foghorn Therapeutics Inc. (-3.09), greater than C4 Therapeutics, Inc. (-3.53), greater than Cyteir Therapeutics, Inc. (-3.52), greater than Prelude Therapeutics Incorporated (-3.49), greater than Rezolute, Inc. (-4.09),

Build a custom stock screener for NGM Biopharmaceuticals, Inc. (NGM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NGM Biopharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

NGM Biopharmaceuticals, Inc. (NGM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like NGM Biopharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.